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Abstract
Background: Regional lymph node (LN) status is a well-known prognostic factor for vulvar carcinoma (VC) patients.
Although the reliable LN assessment in VC is crucial, it presents significant diagnostic problems. We aimed to
identify specific mRNA markers of VC dissemination in the LN and to address the feasibility of predicting the risk of
nodal recurrence by the patterns of gene expression.
Methods: Sentinel and inguinal LN samples from 20 patients who had undergone surgery for stage T1-3, N0-2, M0
primary vulvar squamous cell carcinoma were analyzed. Gene expression profiles were assessed in four metastatic
[LN(+)] and four histologically negative [LN(−)] lymph node samples obtained from four VC patients, by the
Affymetrix U133 Plus 2.0 gene expression microarrays. Of the set of genes of the highest expression in the
metastatic LNs compared to LN(−), seven candidate marker genes were selected: PERP, S100A8, FABP5, SFN, CA12,
JUP and CSTA, and the expression levels of these genes were further analyzed by the real-time reverse transcription
polymerase chain reaction (qRT-PCR) in 71 LN samples.
Results: All of the seven genes in question were significantly increased in LN(+) compared to LN(−) samples. In the
initial validation of the seven putative markers of metastatic LN, the Cox proportional hazard model pointed to SFN,
CA12 and JUP expression to significantly relate to the time to groin recurrence in VC patients.
Conclusions: Our findings first provided evidence that SFN, CA12 and JUP have a potential of marker genes for the
prediction of the groin recurrence LN in VC patients.
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Background
Vulvar carcinoma (VC) is a rare genital malignancy with
age-standardized incidence rates (ASR) ranging world-
wide between 0.5 and 1.5 per 100,000 [1]. The current
ASR in Poland is 1.0, and 436 new cases of VC were
diagnosed and 232 VC-related deaths were recorded in
2009 (age-standardized mortality rate 0.5) [2]. Squamous
cell carcinoma is the most common histological type of
VC, representing approximately 90% of lesions. VC
spreads primarily by the local expansion and via the
lymphatic system.
Lymph node (LN) status is the most important prognos-
tic factor in VC patients [3]. Up to 24% of patients with
LNs clinically considered to be normal have metastases,
while more than 20% of patients with enlarged nodes in
clinical examination are found metastases-free in the histo-
pathologic assessment [4]. Therefore, in many centres the
VC staging comprises an ultrasound-guided fine-needle
biopsy of the suspicious groin LNs and cytologic evalu-
ation of the regional LN status. In early stage VC patients,
the probability of a positive inguinal LN finding is only
11-25% [5]. This means that if all women with early VC
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were assigned to lymphadenectomy, approximately 80% of
them would undergo overtreatment. At present, the con-
cept of sentinel LN biopsy in early stage VC is becoming
increasingly accepted while the problem of optimal treat-
ment of patients with metastatic regional LNs is still being
discussed. Another issue is the assessment of the risk of
metastases in non-sentinel LNs after removal of all posi-
tive sentinel LNs.
Finding a method of an accurate and sensitive pre- or
perioperative determination of pathologic status of groin
nodes would be of a great value to aid therapeutic deci-
sions in early stages of VC. Time-consuming, routine
pathological evaluation of hematoxylin- and eosin-stained
(H&E) LN sections lacks sensitivity. Therefore, a real-time
reverse-transcription PCR (qRT-PCR) is being used in
various tumours to determine the presence of metastatic
cells in LNs [6,7]. However, before the qRT-PCR-based
molecular staging of VC can be applied, clinically relevant
markers [8] need to be identified. In this study, to identify
specific mRNA markers of VC dissemination into LNs,
expression microarrays were employed.
Materials
The material was obtained from 20 patients treated for
vulvar carcinoma in the Maria Sklodowska-Curie Memor-
ial Cancer Centre and Institute of Oncology in Warsaw
between March 2003 and September 2006. Patients with
microscopically confirmed vulvar squamous cell carcin-
oma in clinical stage T1-3, N0-2, M0 and with no prior
treatment for this or any other malignancy were enrolled.
The selected characteristics, including the TNM categories
according to the AJCC (American Joint Committee on
Cancer TNM staging system), of VC patients are pre-
sented in Table 1. Surgery and LN identification were per-
formed as described previously [9]. The median LN count
was 5 nodes in the right groin, range 2–13, while in the
left groin the median LN count was 5.5 nodes, range
0–15. The study was approved by the Independent Eth-
ics Committee of the Maria Sklodowska-Curie Memorial
Cancer Centre and Institute of Oncology in Warsaw
and all patients gave their informed consent. LN speci-
mens were divided into two parts: one part was exam-
ined histologically as described previously [10], the other
was frozen in liquid nitrogen immediately after collec-
tion and stored at −70°C until RNA isolation. Median
follow-up time, determined from the date of surgery to
the date of death or the date of the last interview, was
1.2 years (range 0.43 – 6.29).
Microarray analysis of gene expression profiles was per-
formed in four pairs of LN samples from four VC patients.
One metastatic LN [LN(+)] and one histologically negative
[LN(−)], according to a routine pathological examination
Table 1 Individual patient data
Patient No. Age (years) TNM Stage Histological Grade Histological subtype HPV Status/Type Groin recurrence
5 59.3 T2N0M0 n.d. K n.d. occurred
7 81.3 T2N1M0 G2 K n.d. occurred
8 61.0 T2N1M0 G2 K n.d. occurred
15* 77.2 T2N2M0 G2 K negative occurred
18 78.3 T3N2M0 G1 nK negative not observed
19 51.1 T2N1M0 G3 nK negative not observed
21* 93.9 T2N1M0 G2 K negative not observed
23 71.5 T2N1M0 G2 K negative not observed
25 75.3 T2N0M0 G1 K negative not observed
26 56.8 T2N0M0 G1 K negative not observed
30 45.3 T2N0M0** G3 nK HPV16 not observed
34 71.2 T2N1M0 G2 nK negative not observed
41 80.6 T2N1M0 G1 K negative occurred
45 76.1 T2N0M0 G3 nK negative not observed
46* 64.5 T2N1M0 G3 K negative occurred
49 76.0 T2N0M0 G3 nK negative occurred
51 56.7 T2N2M0 G3 K negative occurred
53 70.3 T2N0M0** G2 K negative occurred
58 52.4 T1bN2M0 G2 K negative not observed
61* 76.6 T2N1M0 G2 nK negative not observed
Abbreviations: K - keratinising squamous cell carcinoma; nK - non-keratinising squamous cell carcinoma; n.d. - not determined; *- LNs of these patients were
incorporated into microarray analysis, **- patients subjected to the unilateral lymphadenectomy.
Kowalewska et al. BMC Cancer 2012, 12:223 Page 2 of 11
http://www.biomedcentral.com/1471-2407/12/223
with H&E, was examined per each of the four patients.
These patients had human papillomavirus (HPV)-negative
tumours, as previously determined using the Linear Array
HPV Detection Kit and Linear Array HPV Genotyping
Test (Roche Molecular Systems, Inc) [10].
A total of 71 right and left LNs (sentinel and inguinal
specimens), from 20 VC patients were included in the
real-time RT-PCR analysis of expression of selected
genes. In a routine pathological examination, 22 LNs




Total RNA was isolated from approximately 200 mg of
pulverised (with the Microdismembrator II, B Braun
Biotech International) LN samples using Nucleospin
RNA L kit (Macherey-Nagel), according to the manufac-
turer’s protocol. RNA quality was assessed using the
Agilent 2100 Bioanalyzer and RNA 6000 Nano Chip Kit
(Agilent Technologies).
Microarray procedure
cDNA synthesis was carried out from 5 μg of RNA with
the One-Cycle cDNA Synthesis Kit (Affymetrix). After
purification (GeneChip Ample Cleanup Module), 7 μl of
double-stranded cDNA were used for biotinylated cRNA
synthesis with IVT Labeling Kit (Affymetrix). The quan-
tity and quality of the obtained cRNA were assessed
using the Agilent 2100 Bioanalyser and RNA 6000 Nano
Chip Kit (Agilent Technologies). Labeled cRNA was
purified using a GeneChip Sample Cleanup Module,
fragmented and hybridized with the Affymetrix Gene-
Chip Human Genome U133 Plus 2.0 arrays. Washing,
staining with streptavidin-phycoerythrin conjugate and
scanning of the arrays in the Affymetrix GeneChip 3000
scanner were performed as recommended by the Affy-
metrix Gene Expression Analysis Technical Manual.
Microarray data analysis
All the arrays were normalized by the GCRMA algo-
rithm using a Bioconductor [11] (version 2.8.1) pack-
age gcrma version 2.14.1. The expression levels were
log2 transformed. We filtered out all the probe sets
with signal level below 7.5 in at least 8 samples.
Genes differentially expressed in involved [LN(+)] and
uninvolved [LN(−)] lymph nodes were searched by a
random-variance t-test, with the statistical significance
threshold set at P< 0.01. To reduce false-differential
gene expression, a Benjamini-Hochberg [12] multiple
testing correction was applied. The full dataset has
been deposited in the Gene Expression Omnibus re-
pository (accession no GSE28442).
The probe sets with differential expression in two sam-
ples - one LN(+) and one LN(−) - obtained from patient
No 15 were chosen to be analyzed first with pumaDE
function from PUMA package version 1.8.1 [13]. Differ-
entially expressed probe sets were annotated with Gene
Ontology (GO) terms (GO.db version 2.2.5) using the
Bioconductor [11] packages GOstats (version 2.8.0) and
package annotate (version 1.20.1). The significance of
differential representation of GO terms between the spe-
cified lists of probe sets was determined by the hyper-
geometric test implemented in GOstats (version 2.8.0). P
values returned by GOstats were corrected for testing of
multiple hypotheses with the Benjamini–Hochberg
method implemented in an R environment (version
2.8.1, The R Foundation for Statistical Computing;
http://www.r-project.org). Adjusted P values of less than
0.05 were considered significant. The same procedure
was applied to the three additional pairs of LN(+) and
LN(−) samples from three patients (No. 21, 46 and 61).
This analysis has provided a set of candidate marker
genes, which were further investigated to define their
tumour specificity using Genevestigator V3, a web-based
microarray database and analysis system [14].
Real time RT-PCR
RNA was extracted from 71 LN samples and 1 μg from
each sample was reverse-transcribed by using the RT²
First Strand Kit (C-03) from SA Biosciences. Custom
PCR arrays (SA Biosciences) were used to simultan-
eously examine the mRNA levels of seven genes of inter-
est according to the manufacturer's protocol.
The arrays also included primers for two housekeeping
genes and three internal controls. Quantitative real-time
PCR analysis was performed with the RT2 Real-Time
PCR Master Mix (SA Biosciences) in the 7500 Fast Real-
Time PCR System (Applied Biosystems), according to
the manufacturer's instructions (SA Biosciences). The
collected data were analyzed using threshold-cycle (Ct)
values for the genes with the SDS 2.1 software (Applied
Biosystems). Normalization was performed based on the
mean values of two housekeeping genes, HMBS and
HSP90AB1, and the relative amounts of RNA for each
gene were calculated by the 2−ΔCT method using
DataAssist™ Software (Applied Biosystems). Expression
levels for each gene were visualized using GraphPadPr-
ism (La Jolla, CA, USA).
Statistical analysis
The significance of difference between the selected gene
expression level in each of LN(+) and LN(−) samples
was assessed by using Wilcoxon test. P< 0.01 was con-
sidered significant.
The Cox proportional-hazard model with Bonferroni
correction for multiple hypotheses testing was applied to
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estimate the effect of gene expression levels in LN sam-
ples on the time to groin recurrence (TTR). The highest
expression value of a given gene of all obtained in differ-
ent LN samples of the same patient was chosen to be
included in the statistical analysis. TTR was calculated
from the date of primary surgery to the date of groin re-
currence. MedCalc (Mariakerke, Belgium) software was
used to generate Kaplan-Meier curves and to compare
TTR using two sided log-rank analysis. The median of
maximum gene expression levels (again, in one of the
nodes examined per patient) in LNs from all the VC
patients enrolled in the study was arbitrarily chosen as a
cut-off value for patient stratification. P< 0.05 was con-
sidered significant.
Results
Identification of expressed genes associated with LN
metastasis
The microarray data from two LN samples, one LN(+)
and one LN(−), from one patient (case No. 15) with a
rapid disease progression, were analyzed using pumaDE
function from the PUMA package 1.8.1 [13]. The filtered
dataset comprised 907 probe-sets with P value below
0.05 (five percent Benjamini-Hochberg false discovery
rate) differentially expressed in these two LN samples.
This list included only up-regulated genes in LN(+) sam-
ples as no genes were found to be reduced in LNs(+)
compared to LNs(−).
To evaluate which biological processes are represented
within the obtained probe set list, the differentially
expressed genes were annotated with the Gene Ontology
(GO) terms. The most significantly over-represented
ontology classes for the genes differentiating between
LN(+) and LN(−) tissue are given in Table 2. The most
up-regulated genes include those coding for epidermal
molecules as well as molecules associated with cell adhe-
sion, locomotory behaviour and inflammatory response.
Gene selection for validation
Based on the results of microarray analysis by the
pumaDE function of PUMA package 1.8.1, we aimed to
select genes with the highest fold-change of expression
between LN(+) and LN(−) obtained from the patient No.
15, and lowest significant adjusted P values, to be
assessed by the quantitative PCR. Genes with over two-
fold differences in expression levels were selected from
the list and further categorized into different functions
and cellular processes. The genes significantly differen-
tially expressed (at P value below 0.01) in the analyzed
LN obtained from patient No. 15 were represented by
408 probe sets (Additional file: 1 Table S1). The genes
selected were those with the highest fold-change values,
represented by specific probe sets (named with the suffix
‘_at’), and those belonging to different GO categories.
The group of genes of interest was further reduced to
those which also proved to differentiate LNs(+) from
LNs(−) in the PUMA analysis of microarray data of the
three additional pairs of nodes from three consecutive
patients (No. 21, 46 and 61). A list of the genes differen-
tially expressed in LN(+) and LN(−) samples obtained
from these four VC patients is presented in the Add-
itional file: 2 Table S2.
Next, only the genes up-regulated in the four LNs(+)
obtained from the four VC patients were analyzed in
Genevestigator V3 system. Genevestigator allowed to
validate their increased expression in vulva, as this re-
pository contains high quality microarray expression
data from experiments performed on 27 non-cancer vul-
var tissue samples (including nine specimens of vulvar
intraepithelial neoplasia, VIN). The genes that showed
high signal intensities in these 27 microarray data sets
were selected. The probe sets were chosen on the basis
of the highest % Present” value generated in the Gene-
vestigator. These values represent a fraction of arrays in
which the signal for a given probe set is above the back-
ground. Finally, seven genes were selected from the
microarray studies: TP53 apoptosis effector - PERP, S100
calcium binding protein A8 - S100A8, fatty acid binding
protein 5 (psoriasis-associated) - FABP5, stratifin - SFN,
carbonic anhydrase 12 - CA12, junction plakoglobin -
JUP and cystatin A - CSTA. Five out of the seven
selected genes, namely, S100A8, FABP5, SFN, JUP and
CSTA, have been described by Hsiao et al. [15] as
“vulva-selective” .
Validation of gene expression levels by real-time RT-PCR
To investigate the reliability of the cDNA microarray
results and to check if our gene selection was correct,
the expression levels of seven genes, PERP, S100A8,
FABP5, SFN, CA12, JUP and CSTA, were measured by
the qRT-PCR in 22 LN(+) and 49 LN(−) samples.
Table 2 Significant Gene Ontology categories
overrepresented among differentially expressed genes
GO category GO term Exp. No. P Pa
GO:0007155 cell adhesion 28.3 1,52E-09 2,07E-06
GO:0008544 epidermis development 2.7 6,70E-09 4,54E-06




GO:0048730 epidermis morphogenesis 1.5 1,15E-05 0,00311
GO:0030216 keratinocyte differentiation 1.0 3,35E-05 0,006311
GO:0007626 locomotory behavior 7.2 3,45E-05 0,006311
GO:0006954 inflammatory response 11.6 3,72E-05 0,006311
Abbreviations: GO – Gene Ontology; Exp. No. - the expected number of
differentially expressed genes (probesets) to be found among genes
annotated to each GO term; P - P value; Pa - adjusted P value.
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We confirmed the significant differences in the expres-
sion levels between uninvolved and involved (as assessed
by routine histopathological analysis) of the all the seven
genes in question (see Figure 1). As shown in Additional
file: 3 Table S3, the expression levels of all of the seven
genes tested by the qRT-PCR, in agreement with the
microarray data, was lower in LN(−) than in LN(+).
Correlations between gene expression levels and time to
groin recurrence in VC patients
Subsequently, we examined a correlation between the
expression levels of the seven selected genes and time to
groin recurrence in VC patients using Cox's propor-
tional hazard analysis. The highest expression value of a
given gene of all obtained in different LN samples of the
same patient was taken into account. Three genes, SFN,
CA12 and JUP, significantly correlated with TTR. High
expression levels of the set of the four remaining genes
in LNs were also associated with shorter TTR, but the
trend did not reach statistical significance (Table 3).
Finally, patients were stratified by the arbitrarily
chosen cut-off values, i.e. the medians of maximum
Figure 1 The PERP, S100A8, FABP5, SFN, CA12, JUP and CSTA expression levels in lymph node samples, measured by qRT-PCR.
Abbreviations: LN(+) - involved lymph node, LN(−) - uninvolved lymph node sample, P – P value computed by the Wilcoxon test.
Table 3 Impact of gene expression levels in LN samples









Abbreviations: TTR – time to groin recurrence, Coef. – Cox-model coefficient of
modification of recurrence hazard by a given variable (i.e. gene expression);
P – P value computed using Cox's proportional hazard analysis.
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gene expression levels in LNs from all the VC
patients enrolled in the study (again, one node with
the highest gene expression was taken into account
per patient). Kaplan-Meier analysis was used for com-
parison of TTR between the groups of patients strati-
fied according to gene expression status, i.e. high
(above the cut-off value) vs low gene expression status
(below the cut-off value) and irrespective of the histo-
pathological evaluation of their LNs status. Initially,
Kaplan-Meier estimates of TTR were used for the
evaluation of the prognostic value of the SFN, CA12
and JUP gene expression, the genes whose expression
was found to correlate significantly with TTR in
above-mentioned COX-model analysis. Further, an
analogous Kaplan-Meier analysis of the remaining four
genes revealed the prognostic value of the expression
level of CSTA gene. The Kaplan-Meier plots show the
association of TTR with the LN expression levels of
SFN, CA12, JUP and CSTA in VC patients, i.e. the
expression levels of these genes predicted TTR (see
Figure 2). The results of comparison of the Kaplan-
Meier estimates for TTR depending on the expression
level of SFN, CA12, JUP and CSTA genes, together
with the cut-off values used for this analysis, are pre-
sented in Table 4. The differences in TTR between
the groups of VC patients stratified by PERP, S100A8
and FABP gene expression levels were not significant
(Kaplan-Meier curves not shown).
Figure 2 Kaplan-Meier estimates of TTR according to SFN, CA12 JUP and CSTA expression status (high vs low) in regional LNs.
Abbreviations: P – P value calculated using the Mantel-Cox log-rank test; high - expression level, i.e. above the cut-off value; low - expression
level, i.e. below the cut-off value (i.e. the median of maximum gene expression levels - as measured in one node per VC patient).
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Discussion
Lymph node status is the most important prognostic
factor in patients with VC [16]. Routine pathological
staging is limited to the microscopic evaluation of
H&E-stained LN sections. Unfortunately, small tumour
foci may occasionally be missed by the pathologist in
this examination [17]. As stated by Regauer [18], senti-
nel LNs of VC patients with even single tumour cells
should be regarded as positive. Thus, to improve detec-
tion of LN metastases, pathological ultrastaging should
ideally be performed [19,20]. This histological work-up
of LNs involves serial sectioning and immunohisto-
chemical analysis; the procedure is labour-intensive and
time-consuming. Real-time RT-PCR technology is more
sensitive, as it allows to detect a very small number of
cells in larger volumes of previously pulverized (or
homogenized) tissues. However, this method carries
some disadvantages, for example it makes morphologic
evaluation of the analyzed samples impossible. There-
fore, a careful marker selection for RT-PCR analysis is a
fundamental issue.
Since there are no molecular markers for diagnosing
VC dissemination, we aimed to identify the potential
mRNA markers of VC dissemination into LNs, and to
verify their prognostic value by correlating their levels
with time to groin recurrence. We used oligonucleotide
microarrays which measure the expression level of over
47,000 transcripts and variants of human genes.
At first, the PUMA package, enabling a comparison
between small-sample gene expression data [21] was
employed, to analyze two samples obtained from one pa-
tient, who underwent a rapid progression of the disease
during the follow-up time, with local recurrence, and
groin recurrence in the same groin where the LN(+),
and died due to cancer progression. The PUMA analysis
produced a list of genes differentially expressed in LN(+)
and LN(−). The most significantly over-represented gene
ontology (GO) classes in the list included epidermal
molecules. Thus, some of the differentially expressed
genes are those specifically expressed in the primary
tumour site. This finding testifies the methodology used
for the comparison of the single microarray experiments.
Similar results were obtained for the three additional
pairs of LNs obtained from three patients.
Interestingly, gene expression signature distinguishing
between the four pairs of histologically positive and
negative LNs comprised no genes down-regulated in the
metastatic LNs of the same patients. A possible explan-
ation of this observation is that only transcripts that
were highly up-regulated in the metastatic cells could be
distinguished from the background of the numerous
non-cancer cells as an “added value” while down-
regulated transcripts, i.e. transcripts’ deprivation, would
not be noticed in this background environment.
The consecutive steps of narrowing-down of the list
of the differentially expressed in the four LNs obtained
from the four VC patients genes led us to the choice
of seven genes, namely PERP, S100A8, FABP5, SFN,
CA12, JUP and CSTA, to be validated by the real time
RT-PCR. Gene expression data of 27 non-cancer vulvar
tissue samples deposited in the Genevestigator V3 sys-
tem [22,23] have shown that these seven genes are
regularly up-regulated in vulvar tissue. In addition,
Hsiao et al. [15], who created a compendium of tissue-
selective genes based on microarray data, described five
of these genes as “vulva-selective.” This strongly sup-
ports tissue specificity of the selected genes for the pri-
mary tumour site.
To our knowledge, this is the first time that these genes
have been linked to VC dissemination. PERP, as a compo-
nent of intercellular desmosome junctions, plays a role in
epithelial integrity and cell-cell adhesion [24] and consti-
tutes a proapoptotic transcriptional target of TP53 [25].
PERP-deficiency promotes cancer by enhancing cell sur-
vival, desmosome loss, and inflammation [26]. S100 cal-
cium binding protein A8, S100A8, belongs to S100
proteins, a family of EF-hand signalling proteins [27]. The
complex of S100A8 and S100A9 called calprotectin
induces a proinflammatory and thrombogenic response,
and is involved in danger signalling; what is more, its
stimulation results in a loss of cell–cell contacts [28,29].
S100A8/S100A9 expression is increased in patients with
various tumours, being involved in invasion and migration
processes [30,31]. S100A8/9 expression is minimal in
Table 4 The results of the comparison of Kaplan-Meier estimates for TTR for VC patients according to their LN gene
expression levels
Transcript TTR for patients with high expression level TTR for patients with
low expression level
P
Cut-off Value Median TTR (months) HR; CI Median TTR (months)
SFN 0.4815 8.7 0.21;95% CI, 0.06-0.86 not reached 0.029
CA12 0.23 6.9 0.16;95% CI, 0.04-0.61 not reached 0.008
JUP 0.4815 6.89 0.18;95% CI, 0.05-0.74 not reached 0.016
CSTA 0.03 6.89 0.17;95% CI, 0.04-0.66 not reached 0.011
Abbreviations: TTR – time to groin recurrence; HR – hazard ratio; CI – confidence interval; Cut-off Value - the arbitrarily chosen cut-off for gene expression value
used for patient stratification; P – P value calculated with the use of the log-rank test.
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normal epidermis and is elevated in skin diseases [32].
However, Dell'oste et al. [33] showed that in HPV-
immortalized keratinocytes S100A8/9 expression was
downregulated. Fatty acid binding protein 5 (psoriasis-
associated, FABP5), found in epidermal cells, was first
identified to be up-regulated in psoriasis keratinocytes
[34]. In cancer cells, FABP5 increases cell proliferation
and invasiveness, as recently demonstrated in oral squa-
mous cell carcinoma [35] where its expression may be
HPV-related [36]. In non-cancer keratinocytes FABP5 ele-
vation may be necessary for the activation of cell motility
during epidermal wound healing [37]. Stratifin, SFN (14-
3-3 sigma), plays a role in various cellular processes being
the most cancer-associated 14-3-3 isoform [38]. 14-3-3
sigma expression is lost in numerous tumours [38], in-
cluding VC [39], while its increased expression could be
associated with a loss of TP53 function [40,41]. However,
Wang et al. [42] found high levels of SFN detected immu-
nohistochemically in over 70% of analyzed VC tumors,
significantly correlating to large tumor diameter and deep
invasion. Importantly, 14-3-3 sigma protein is present in
various normal epithelia and absent in LNs [43,44], and
lymphocytes may express its mRNA at relatively low levels
[45]. Carbonic anhydrase XII is one of the tumour-
associated carbonic anhydrases. The enzyme is overex-
pressed under hypoxic conditions and constitutes a pos-
sible target for anticancer therapy [46,47]. Junction
plakoglobin, JUP, a member of the catenin family, is
present both in desmosomes and in intermediate junc-
tions [48]. The majority of studies suggest that plakoglo-
bin has a tumour suppressor role [49]. Cystatin A (stefin
A), CSTA, functions as a cysteine protease inhibitor and
plays a role in epidermal development and maintenance.
Serum level of CSTA has been proposed as a tool predict-
ing nodal stage and poor prognosis in nasopharyngeal car-
cinoma [50].
The comparison of LNs(+) with LNs(−) confirmed
that LNs(+) express significantly more transcripts of
PERP, S100A8, FABP5, SFN, CA12, JUP and CSTA. The
results of PCR analysis showed particularly increased
expression of S100A8 and SFN in the metastatic LNs,
where there was over 10-fold change of the mean ex-
pression level. Higher expression of PERP, FABP5,
CA12, JUP and CSTA were also found, but the differ-
ences were lower.
The significance of gene expression levels in LN samples
for time to groin recurrence (TTR) was statistically ana-
lyzed using Cox's proportional hazard model. A coefficient
computed by this method for each variable expression of
“predictor” genes indicates the direction and degree of
flexing that the predictor has on the TTR curve. A positive
value of coefficients indicated that larger values of the ex-
pression were associated with greater groin recurrence
rates. Two genes, namely SFN and CA12, were found
significantly predictive of such recurrence. High expres-
sion levels of the other genes of the set of five in LNs were
also associated with shorter TTRs, but the trend did not
reach statistical significance.
The log-rank test used for testing significance of the
TTR functions in Kaplan-Meier analysis yielded signifi-
cant P values for separating the two groups of VC
patients with different TTR according to their LN gene
expression levels of SFN, CA12, JUP and CSTA. Patients
with low expression of these genes had a superior TTR
values of not reached versus 6.9 to 8.7 months.
It is worth noting that our study had some important
limitations. Firstly, only seven of the most differentially
expressed genes in the microarray experiment were ana-
lyzed by the qRT-PCR. Notwithstanding, the remaining
genes (see Additional file: 2 Table S2) are candidates for
validation in further studies. Secondly, LN assessment
was based on routine pathological evaluation with H&E
staining, while the state-of-the-art would be to perform
ultrastaging on the excised LNs. Lastly, Kaplan-Meier
analysis of TTR that was applied to SFN, CA12, JUP and
CSTA expression, should be considered as just an illus-
tration of potential clinical use of the identified marker
genes. Future studies should include more patients to as-
sure a better assessment of the novel markers’ perform-
ance. Such studies should also provide better cut-off
values for patients’ stratification than the arbitrarily
chosen median expression levels in LNs, and enable the
ROC curve analysis. Importantly, our microarray data
were obtained for HPV-negative patients in order to ex-
clude the interference of the infection with the expres-
sion results and to focus on metastasis-associated genes’
selection. However, patients with HPV infection should
also be enrolled in future studies to assess the influence
of HPV on the markers’ performance.
Groin recurrences from VC are often fatal. Unfortu-
nately, “the optimum mode of treatment and predictive
factors for patients with groin recurrences are unknown”
[51]. The size of LN metastases correlates with survival
in patients with early [52] and advanced [53] stage VC.
On the other hand, “inguinofemoral lymphadenectomy
can be avoided when the sentinel node is negative for
disease” [54]. However, although Oonk and colleagues
[52] reported that the risk of non-sentinel LN involve-
ment increases with size of sentinel LN metastases, they
were unable to determine the cut-off size below which
the risk of non-sentinel LN metastases would be incon-
siderable. Therefore, the authors concluded that all
patients with sentinel LN metastases - regardless of their
size - should undergo additional groin treatment. The
risk of additional metastases when only isolated tumour
cells are present in the sentinel LN is 4% [55]. Still, ap-
proximately 12% of early-stage VC patients with a nega-
tive sentinel LN develop local recurrence” [54,56].
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For the reasons discussed above, novel means to better
stratify early-stage VC patients in order to optimize
treatment modality, i.e. a tool to decide who should not
undergo lymphadenectomy vs who should receive add-
itional treatment to the groin would be highly beneficial.
Further validation of markers and development of mo-
lecular tests is indispensable for the reliable up- or
down-staging of LNs. Our results may ideally be used to
develop a test that could be used during surgery to de-
cide whether to remove inguinal LNs, similarly to the
RT-PCR based, FDA-approved GeneSearch™ Breast
Lymph Node (BLN) Assay (Veridex, LLC, Warren, NJ),
used for the rapid intra-operative detection of sentinel
LN metastases in breast cancer. Such tests may reduce
the need for a second surgery for the axillary LN dissec-
tion [57-59]. As sentinel node procedure was confirmed
to be safe in the early-stage VC patients [54], tests simi-
lar to GeneSearch™ should also be of clinical utility for
VC patients.
Conclusions
To conclude, the performance of qRT-PCR assays
employing the LN(+) marker genes that we have identi-
fied, PERP, S100A8, FABP5, SFN, CA12, JUP and CSTA,
may provide a promising tool for intra-operative sentinel
LN evaluation in VC patients. Moreover, all the above
marker genes have a potential of prognostic biomarkers,
however, before their incorporation into clinical setting
further studies are necessary to confirm their prognostic
value in the qRT-PCR assays.
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